The Phase 1 ACCEL Trial: Actinium-225-PSMA-62
/0 Comments/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxOncoACP3: A Potential Game-Changer in Prostate Cancer Theranostics —Why?
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxENV105 to Reverse Resistance to ADT and ARSI
/1 Comment/in Clinical Trial, Metastatic, Phase 2/by MaxUpdate: 67Cu-SAR-bisPSMA for mCRPC Has Been Fast-Tracked by FDA
/0 Comments/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxASCO GU 2025: Combination Therapy with Cabozantinib and Atezolizumab Shows Promise for Advanced Prostate Cancer
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxTransdermal Estradiol Patches Show Promise as a Safer Alternative to Traditional Hormone Therapy in Metastatic Prostate Cancer
/0 Comments/in Clinical Trial, Metastatic, Phase 2/by MaxTalazoparib Plus Enzalutamide in HRR-Deficient mCRPC: Final Overall Survival Results from TALAPRO-2
/0 Comments/in Clinical Trial, Metastatic, Phase 3/by MaxASCO GU 2025: New Drug CBP-1018 Shows Promise for Advanced Prostate Cancer in Clinical Trial
/0 Comments/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
225Ac abiraterone acetate ADC ADT AI ai in healthcare antibody-drug conjugate apalutamide ASCO 2025 ATM bispecific antibody bone metastases bone metastasis BRCA cancer immunotherapy castration-resistant prostate cancer CDK12 clinical trial clinical trials crispr CYP11A1 inhibitor darolutamide drug repurposing drug resistance enzalutamide HRR immune checkpoint inhibitors immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA nanotechnology olaparib oncolytic virus personalized medicine prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data T-cell therapy theranostics
Latest Posts
- Newsletter 23/2025 June 8, 2025
- Protein Design Leaps Forward Thanks to AI June 5, 2025
- Phase 1 Trial of XL309: USP1 Inhibitor Targeting DNA Repair in Solid Tumors June 5, 2025
- UPDATE About ACE-232: Phase 1 Trial of a Novel CYP11A1 Inhibitor for mCRPC June 5, 2025